Clinical trials: Depression - Major Depressive Disorder
Major Depressive Disorder
A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder
Major depressive disorder (MDD) is a serious medical illness associated with significant suicidal risk and marked disability. Despite the availability of numerous treatments, achievement of consistent and favorable long-term…
- Trial name
- NCT03538691
- Testing
- Brexpiprazole, Antidepressant therapy
- Where
- United States
- Volunteers
- 1,149 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depression, Depressive Disorder
Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)
This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of TNX-601 ER monotherapy versus placebo in patients with Major Depressive Disorder (MDD).
- Conditions
- Depression, Depressive Disorder, Depressive Symptoms, Depressive Disorder, Major
- Trial name
- UPLIFT (NCT05686408)
- Testing
- TNX-601 ER
- Where
- 27 sites in United States
- Volunteers
- 132 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Major Depressive Disorder, Dysthymia
Dichotic Listening as a Predictor of Medication Response in Depression
This study will recruit 100 depressed patients to test whether the previous finding of an association between treatment response (with treatment groups including placebo, imipramine, and fluoxetine) and preferences of hemispheric…
- Trial name
- NCT00404755
- Testing
- escitalopram, bupropion, imipramine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone
The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD who have had an inadequate response to…
- Trial name
- NCT03738215
- Testing
- Cariprazine
- Where
- 125 sites in United States, Bulgaria and 5 more
- Volunteers
- 759 people
- Sponsor
- AbbVie
Treatment Resistant Depression
Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression
This study is looking at the efficacy, rapidity, safety, and tolerability of two doses of oral CERC-501 for treating patients with treatment resistant depression who are taking an antidepressant that is not working for them.
- Trial name
- RAPID KOR (NCT01913535)
- Testing
- CERC-501
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder, Dysthymia
A Study of L-DOPA for Depression and Slowing in Older Adults
Individuals with Late Life Depression (LLD) often have cognitive problems, particularly problems with memory, attention, and problem solving, all of which contribute to antidepressant non-response.
- Conditions
- Major Depressive Disorder, Dysthymia, Depression Not Otherwise Specified, Decreased Processing Speed
- Trial name
- NCT02744391
- Testing
- Levodopa
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
Evaluation of a Mental Health Physician Support Program in Nova Scotia
The aim of this study is to test the program's effectiveness in a primary care setting in reducing stigma among medical personnel, increasing the comfort level of physicians and staff in providing care to those living with mental…
- Trial name
- NCT01975948
- Testing
- Mental Health Practice Support Program, Treatment as Usual
- Where
- Canada
- Volunteers
- 285 people
- Sponsor
- Nova Scotia Health Authority
Major Depressive Disorder
Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
To evaluate the long-term safety and tolerability of flexible doses, 15 and 20 mg/day, of Vortioxetine over a period of 52 weeks in patients with Major Depressive Disorder (MDD)
- Trial name
- NCT01323478
- Testing
- Vortioxetine (Lu AA21004)
- Volunteers
- 71 people
- Sponsor
- H. Lundbeck A/S
Adjunctive Treatment of Major Depressive Disorder (MDD)
A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder
The study is a Phase 2, double-blind, randomized, placebo-controlled study in Major Depressive Disorder (MDD) participants with an inadequate response to standard antidepressants The objective of the study is to assess CLE-100…
- Trial name
- SOLEO (NCT06340958)
- Testing
- CLE-100
- Where
- 23 sites in United States
- Volunteers
- 99 people
- Sponsor
- Clexio Biosciences Ltd.
Major Depressive Disorder
Epigenetic Regulation of BDNF in Major Depression
The investigators will (1) detect the associations between brain-derived neurotrophic factor (BDNF) DNA methylation, histone modification, depressive symptoms, suicidal behavior and antidepressant responses in major depressive…
- Trial name
- NCT01182103
- Where
- Taiwan
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Major Depressive Disorder
Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder
The primary objective of the study was to determine the effects of 10-week adjunctive supplementation with 2 doses of LCn-3 fatty acids (fish oil) on cortical functional activity and biochemistry in adolescents with MDD.
- Trial name
- NCT00511810
- Testing
- Low Dose Fish Oil, High Dose Fish Oil
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Cincinnati
Treatment Resistant Depression
KET-RO Plus RO DBT for Treatment Resistant Depression
This pilot study will assess the safety and feasibility of intravenous (IV) ketamine combined with RO DBT in young adults with Treatment-Resistant Depression (TRD).
- Trial name
- KET-RO (NCT06138691)
- Testing
- Ketamine Infusion plus RO DBT
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Washington University School of Medicine
Major Depression, Dysthymia
Treating Depression Among Low-Income Patients With Cancer
The ADAPt-C collaborative depression care model is designed to: improve depression symptom reduction in the intervention group over the modestly enhanced usual care group of low-income, predominantly Hispanic, patients with…
- Trial name
- ADAPt-C (NCT00565110)
- Testing
- ADAPt-C intervention
- Where
- United States
- Volunteers
- 472 people
- Sponsor
- University of Southern California
Major Depressive Disorder
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
The purpose of this study is to evaluate the safety and efficacy of an 8-week double-masked treatment of tasimelteon or placebo in male and female subjects with Major Depressive Disorder.
- Trial name
- MAGELLAN (NCT01428661)
- Testing
- tasimelteon
- Where
- 40 sites in United States
- Volunteers
- 507 people
- Sponsor
- Vanda Pharmaceuticals
Major Depressive Disorder
Safety and Effectiveness of NeuroStar® Transcranial Magnetic Stimulation (TMS) Therapy in Depressed Adolescents
To evaluate the safety and efficacy of daily, active Neurostar® TMS (when compared with sham treatment) in adolescents meeting criteria for Major Depressive Disorder (MDD).
- Trial name
- NCT02586688
- Testing
- Active NeuroStar® Transcranial Magnetic Stimulation (TMS)
- Where
- 13 sites in United States
- Volunteers
- 112 people
- Sponsor
- Neuronetics
Major Depressive Disorder, MDD
Transcranial Alternating Current Stimulation for Major Depressive Disorder
Investigating the effects of non-invasive transcranial alternating current stimulation (tACS) on patients with Major Depressive Disorder (MDD).
- Trial name
- MDD (NCT02339285)
- Testing
- tACS (alpha), tACS (gamma)
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of North Carolina, Chapel Hill
Seasonal Affective Disorder
Environmental Treatment for Seasonal Affective Disorder (SAD)
The purpose is to study treatments of Seasonal Affective Disorder (SAD).
- Trial name
- NCT00139997
- Testing
- Litebook treatment devices, Inactivated negative ion generator
- Where
- 5 sites in United States, Canada and 1 more
- Volunteers
- 26 people
- Sponsor
- Yale University
Depressive Disorder, Major Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) In The Treatment Of Child and Adolescent Outpatients With Major Depressive Disorder
The primary purpose of this study is to evaluate the long-term safety and tolerability of Desvenlafaxine Succinate Sustained-Release (DVS SR) in child and adolescent outpatients with major depressive disorder.
- Trial name
- NCT00669110
- Testing
- Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depressive Disorder, Major, Unipolar Depression
Deep Brain Stimulation for Major Depressive Disorder
This study is designed as a prospective, multi-centered, double-blind, randomized, controlled 12-month pivotal study to evaluate the safety and efficacy of the ANS Libra® Deep Brain Stimulation System for patients with major…
- Trial name
- NCT00617162
- Testing
- Deep Brain Stimulation, Libra Deep Brain Stimulation System
- Where
- 13 sites in United States, Canada and 1 more
- Volunteers
- 125 people
- Sponsor
- Abbott Medical Devices
Major Depressive Disorder, Posttraumatic Stress Disorder
Comparing Individual Therapies for Veterans With Depression, PTSD, and Panic Disorder
Cognitive behavioral therapy (CBT) is a brief, efficient, and effective treatment for individuals with depressive/anxiety disorders.
- Conditions
- Major Depressive Disorder, Posttraumatic Stress Disorder, Panic Disorder and Agoraphobia
- Trial name
- NCT04293341
- Testing
- Transdiagnostic Behavior Therapy, Cognitive Processing Therapy for PTSD, Cognitive Behavioral Therapy for MDD
- Where
- United States
- Volunteers
- 304 people
- Sponsor
- VA Office of Research and Development